Longitudinal study of circulating miR-122 in a rat model of non-alcoholic fatty liver disease

作者: Hiroya Yamada , Koji Ohashi , Koji Suzuki , Eiji Munetsuna , Yoshitaka Ando

DOI: 10.1016/J.CCA.2015.05.002

关键词:

摘要: Abstract Background Circulating microRNAs (miRs) may be promising biomarkers for several diseases. We previously found that miR-122 can function as a biomarker non-alcoholic fatty liver disease (NAFLD). However, little is known regarding the time course of circulating levels during development NAFLD. Here, we examined using rat model Methods To clarify changes in serum NAFLD, experimental rats were fed high-fat diet (HFD) 2–10 weeks, while control received standard chow. Serum and tissue was collected from all animals at 2, 6, 10 weeks feeding. Clinical laboratory parameters (cholesterol, TG, AST, ALT, NEFA) determined by biochemistry analyzer. Hepatic lipid accumulation estimated Oil red O staining. then measured real-time polymerase chain reaction. Results Over feeding, body weight, total lipids, triacylglycerol increased HFD group compared to group. no significant alanine aminotransferase activity observed, suggesting NAFLD status mild. In contrast, observed drastic up-regulation levels. Our findings suggest level indeed useful assessing early might superior clinical markers traditionally used monitor hepatic disease.

参考文章(22)
Valerio Nobili, Lucia Pacifico, Claudio Chiesa, Paola Verdecchia, Caterina Anania, Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World Journal of Gastroenterology. ,vol. 17, pp. 3082- 3091 ,(2011) , 10.3748/WJG.V17.I26.3082
Catherine Jopling, Liver-specific microRNA-122: Biogenesis and function RNA Biology. ,vol. 9, pp. 137- 142 ,(2012) , 10.4161/RNA.18827
Hiroshi Ohkawa, Nobuko Ohishi, Kunio Yagi, Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction Analytical Biochemistry. ,vol. 95, pp. 351- 358 ,(1979) , 10.1016/0003-2697(79)90738-3
C MATTEONI, Z YOUNOSSI, T GRAMLICH, N BOPARAI, Y LIU, A MCCULLOUGH, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology. ,vol. 116, pp. 1413- 1419 ,(1999) , 10.1016/S0016-5085(99)70506-8
Silvia Cermelli, Anna Ruggieri, Jorge A. Marrero, George N. Ioannou, Laura Beretta, Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease PLoS ONE. ,vol. 6, pp. e23937- ,(2011) , 10.1371/JOURNAL.PONE.0023937
Charlene A. Wong, Maria Rosario G. Araneta, Elizabeth Barrett-Connor, John Alcaraz, Donna Castañeda, Carol Macera, Probable NAFLD, by ALT levels, and diabetes among Filipino-American Women Diabetes Research and Clinical Practice. ,vol. 79, pp. 133- 140 ,(2008) , 10.1016/J.DIABRES.2007.07.012
Hiroya Yamada, Mitsuyasu Itoh, Izumi Hiratsuka, Shuji Hashimoto, Circulating microRNAs in autoimmune thyroid diseases. Clinical Endocrinology. ,vol. 81, pp. 276- 281 ,(2014) , 10.1111/CEN.12432
Hiroya Yamada, Koji Suzuki, Naohiro Ichino, Yoshitaka Ando, Akira Sawada, Keisuke Osakabe, Keiko Sugimoto, Koji Ohashi, Ryouji Teradaira, Takashi Inoue, Nobuyuki Hamajima, Shuji Hashimoto, Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver Clinica Chimica Acta. ,vol. 424, pp. 99- 103 ,(2013) , 10.1016/J.CCA.2013.05.021
Yi W Kong, David Ferland-McCollough, Thomas J Jackson, Martin Bushell, None, microRNAs in cancer management. Lancet Oncology. ,vol. 13, ,(2012) , 10.1016/S1470-2045(12)70073-6